OBJECTIVE: To examine predictors of treatment outcome in IBS-patients who participated in a randomized controlled trial in primary care, where 149 irritable bowel syndrome (IBS) patients were randomized to mebeverine hydrochloride (n=77) or mebeverine+cognitive behavior therapy (CBT) (n=72). CBT offered additional benefit over mebeverine alone. METHODS: Regression analyses were used to identify predictors of work and social adjustment 12 months after treatment ended. The intervention groups were analyzed separately in order to look at the separate effects in each group. RESULTS: Lower levels of psychological distress (anxiety and depression) at baseline predicted a good outcome in the mebeverine group [beta=0.388 (95% CI: 0.065-0.936), P=.025] but not in the mebeverine+CBT group. In the adjusted model for the mebeverine+CBT group less adaptive IBS related behavioral coping predicted a good outcome [beta=0.285 (95% CI: 0.002-0.210), P=.045]. CONCLUSION: Different factors are associated with outcome depending on the treatment received. At assessment clinicians should assess patients coping styles and may want to consider recommending CBT to those patients with IBS in primary care who are engaging in unhelpful coping behavior. Copyright 2010 Elsevier Inc. All rights reserved.
RCT Entities:
OBJECTIVE: To examine predictors of treatment outcome in IBS-patients who participated in a randomized controlled trial in primary care, where 149 irritable bowel syndrome (IBS) patients were randomized to mebeverine hydrochloride (n=77) or mebeverine+cognitive behavior therapy (CBT) (n=72). CBT offered additional benefit over mebeverine alone. METHODS: Regression analyses were used to identify predictors of work and social adjustment 12 months after treatment ended. The intervention groups were analyzed separately in order to look at the separate effects in each group. RESULTS: Lower levels of psychological distress (anxiety and depression) at baseline predicted a good outcome in the mebeverine group [beta=0.388 (95% CI: 0.065-0.936), P=.025] but not in the mebeverine+CBT group. In the adjusted model for the mebeverine+CBT group less adaptive IBS related behavioral coping predicted a good outcome [beta=0.285 (95% CI: 0.002-0.210), P=.045]. CONCLUSION: Different factors are associated with outcome depending on the treatment received. At assessment clinicians should assess patients coping styles and may want to consider recommending CBT to those patients with IBS in primary care who are engaging in unhelpful coping behavior. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Hsiu-Feng Hsueh; Monica E Jarrett; Kevin C Cain; Robert L Burr; Wimon Deechakawan; Margaret M Heitkemper Journal: Gastroenterol Nurs Date: 2011 Mar-Apr Impact factor: 0.978
Authors: Lisa Ruepert; A Otto Quartero; Niek J de Wit; Geert J van der Heijden; Gregory Rubin; Jean Wm Muris Journal: Cochrane Database Syst Rev Date: 2011-08-10
Authors: Brjánn Ljótsson; Gerhard Andersson; Erik Andersson; Erik Hedman; Perjohan Lindfors; Sergej Andréewitch; Christian Rück; Nils Lindefors Journal: BMC Gastroenterol Date: 2011-10-12 Impact factor: 3.067
Authors: Brjánn Ljótsson; Erik Andersson; Perjohan Lindfors; Jeffrey M Lackner; Karin Grönberg; Katarina Molin; Johanna Norén; Karin Romberg; Evelyn Andersson; Timo Hursti; Hugo Hesser; Erik Hedman Journal: BMC Gastroenterol Date: 2013-11-19 Impact factor: 3.067